Detail View
Reactive Oxygen Species-Responsive Miktoarm Amphiphile for Triggered Intracellular Release of Anti-Cancer Therapeutics
WEB OF SCIENCE
SCOPUS
- Title
- Reactive Oxygen Species-Responsive Miktoarm Amphiphile for Triggered Intracellular Release of Anti-Cancer Therapeutics
- DGIST Authors
- Kim, Hyun-Chul ; Kim, Eunjoo ; Lee, Se Geun ; Lee, Sung Jun ; Jeong, Sang Won ; Lee, Young Jae ; Kwon, Mi Kyung ; Choi, Seong-Kyoon ; Hwang, Jun Seong ; Choi, Eun-Sook
- Issued Date
- 2021-12
- Citation
- Kim, Hyun-Chul. (2021-12). Reactive Oxygen Species-Responsive Miktoarm Amphiphile for Triggered Intracellular Release of Anti-Cancer Therapeutics. doi: 10.3390/polym13244418
- Type
- Article
- Author Keywords
- drug delivery system ; miktoarm amphiphile ; ROS-responsive ; tocopheryl derivate ; tumor therapy
- Keywords
- BLOCK-COPOLYMERS ; DRUG-DELIVERY ; VITAMIN-E ; MICELLES ; CANCER ; POLYMER ; NANOCARRIERS ; EFFICIENT ; BIODISTRIBUTION ; NANOPARTICLES
- ISSN
- 2073-4360
- Abstract
-
Reactive oxygen species (ROS)-responsive nanocarriers have received considerable research attention as putative cancer treatments because their tumor cell targets have high ROS levels. Here, we synthesized a miktoarm amphiphile of dithioketal-linked ditocopheryl polyethylene glycol (DTTP) by introducing ROS-cleavable thioketal groups as linkers between the hydrophilic and hydrophobic moieties. We used the product as a carrier for the controlled release of doxorubicin (DOX). DTTP has a critical micelle concentration (CMC) as low as 1.55 µg/mL (4.18 × 10−4 mM), encapsulation efficiency as high as 43.6 ± 0.23% and 14.6 nm particle size. The DTTP micelles were very responsive to ROS and released their DOX loads in a controlled manner. The tocopheryl derivates linked to DTTP generated ROS and added to the intracellular ROS in MCF-7 cancer cells but not in HEK-293 normal cells. In vitro cytotoxicity assays demonstrated that DOX-encapsulated DTTP micelles displayed strong antitumor activity but only slightly increased apoptosis in normal cells. This ROS-triggered, self-accelerating drug release device has high therapeutic efficacy and could be a practical new strategy for the clinical application of ROS-responsive drug delivery systems. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
더보기
- Publisher
- MDPI AG
File Downloads
공유
Total Views & Downloads
???jsp.display-item.statistics.view???: , ???jsp.display-item.statistics.download???:
